Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.

Charles RP, Iezza G, Amendola E, Dankort D, McMahon M.

Cancer Res. 2011 Jun 1;71(11):3863-71. doi: 10.1158/0008-5472.CAN-10-4463.

2.

TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.

Zou M, Baitei EY, Al-Rijjal RA, Parhar RS, Al-Mohanna FA, Kimura S, Pritchard C, Binessa HA, Alzahrani AS, Al-Khalaf HH, Hawwari A, Akhtar M, Assiri AM, Meyer BF, Shi Y.

Oncogene. 2016 Apr 14;35(15):1909-18. doi: 10.1038/onc.2015.253.

PMID:
26477313
3.

BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.

Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, Criscimanna A, Di Blasi F, Pitrone M, Zerilli M, Amato MC, Spinelli G, Carina V, Modica G, Latteri MA, Galluzzo A, Giordano C.

Endocr Relat Cancer. 2011 Nov 14;18(6):669-85. doi: 10.1530/ERC-11-0076.

4.

BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.

Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V.

Mod Pathol. 2010 Aug;23(8):1052-60. doi: 10.1038/modpathol.2010.86.

5.

BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H.

Endocrine. 2012 Oct;42(2):404-10.

PMID:
22426956
6.

High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.

de Biase D, Cesari V, Visani M, Casadei GP, Cremonini N, Gandolfi G, Sancisi V, Ragazzi M, Pession A, Ciarrocchi A, Tallini G.

J Clin Endocrinol Metab. 2014 Aug;99(8):E1530-8. doi: 10.1210/jc.2013-4389.

PMID:
24780046
7.

Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.

Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, Fagin JA.

Cancer Res. 2005 Mar 15;65(6):2465-73.

8.

Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma.

Lee SJ, Lee MH, Kim DW, Lee S, Huang S, Ryu MJ, Kim YK, Kim SJ, Kim SJ, Hwang JH, Oh S, Cho H, Kim JM, Lim DS, Jo YS, Shong M.

PLoS One. 2011 Jan 13;6(1):e16180. doi: 10.1371/journal.pone.0016180.

9.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

10.

Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.

Duquette M, Sadow PM, Husain A, Sims JN, Antonello ZA, Fischer AH, Song C, Castellanos-Rizaldos E, Makrigiorgos GM, Kurebayashi J, Nose V, Van Hummelen P, Bronson RT, Vinco M, Giordano TJ, Dias-Santagata D, Pandolfi PP, Nucera C.

Oncotarget. 2015 Dec 15;6(40):42445-67. doi: 10.18632/oncotarget.6442.

11.

The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.

Vanden Borre P, McFadden DG, Gunda V, Sadow PM, Varmeh S, Bernasconi M, Jacks T, Parangi S.

Thyroid. 2014 Apr;24(4):705-14. doi: 10.1089/thy.2013.0483.

12.
13.

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.

Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies TF, Weinstein LS, Chen M, Rosen N, Ghossein R, Knauf JA, Fagin JA.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1615-20. doi: 10.1073/pnas.1015557108.

14.

Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.

Milewska M, Romano D, Herrero A, Guerriero ML, Birtwistle M, Quehenberger F, Hatzl S, Kholodenko BN, Segatto O, Kolch W, Zebisch A.

PLoS One. 2015 Jun 12;10(6):e0129859. doi: 10.1371/journal.pone.0129859.

15.

BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.

Tang KT, Lee CH.

J Chin Med Assoc. 2010 Mar;73(3):113-28. doi: 10.1016/S1726-4901(10)70025-3. Review.

16.

The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.

Daliri M, Abbaszadegan MR, Bahar MM, Arabi A, Yadollahi M, Ghafari A, Taghehchian N, Zakavi SR.

Endocr Res. 2014;39(4):189-93. doi: 10.3109/07435800.2013.879169.

PMID:
24679337
17.

[Expression of BRAF V600E mutation in different thyroid lesions].

Wang W, Li XH, Zhang YH, Li J, Chen J, Zhao P, Li QY, Xiang JJ, Li X, Xu RJ.

Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):354-7. Chinese.

PMID:
21875464
18.

Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.

Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro HK, Kim JM, Shong M.

J Clin Endocrinol Metab. 2006 Sep;91(9):3667-70.

PMID:
16772349
19.

The role of BRAF in the pathogenesis of thyroid carcinoma.

Li DD, Zhang YF, Xu HX, Zhang XP.

Front Biosci (Landmark Ed). 2015 Jun 1;20:1068-78. Review.

PMID:
25961545
20.

Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.

Shimamura M, Nakahara M, Orim F, Kurashige T, Mitsutake N, Nakashima M, Kondo S, Yamada M, Taguchi R, Kimura S, Nagayama Y.

Endocrinology. 2013 Nov;154(11):4423-30. doi: 10.1210/en.2013-1174.

PMID:
23970782

Supplemental Content

Support Center